CIBERESUCICOVID is a fundamental study to improve care of critical patients of COVID-19. Its results will definitely contribute to improve diagnosis and treatment, to decrease mortality, and improve the quality of life of survivors
JOIN THE STUDYCollaborate with us!
Those interested in participating in the investigation may directly contact the Study Coordinator, Adrián Ceccato, by clicking on the « join the study » button.
Description of the Study:
- Title: Personalized Risk and Prognosis Factors and Follow-up at One Year of the Patients Hospitalized in the Spanish Intensive Care Units Infected with COVID-19 (CIBERESUCICOVID).
- Principal Investigator: Antoni Torres Martí.
- Co-Investigators: Ferran Barbé Illa, Ricard Ferrer, Jesús Bermejo, Alejandro Rodríguez, Rosario Menéndez and et al.
- Centers of Implementation: At more than 50 Spanish ICUs.
- Study Population: 5000 patients.
Objectives of the Study:
Principal Objective: To determine, through artificial intelligence analysis, which are the risk and prognosis factors of patients infected with COVID-19 that are hospitalized in the Spanish ICUs since the pandemic started in Spain and until it is finished.
Secondary Objectives:
(1) To perform the follow-up of patients since their release from the ICU and from the hospital until one year later, to determine mortality at six months and at one year, and the repercussions in respiratory and cardiovascular function, as well as in the quality of life.
(2) To perform the epigenetic study of those cases in which a blood sample is obtained.
(3) To evaluate the impact over the prognosis of a panel of biomarkers in physiological routes which are key in the pathogenesis of the disease, with the goal of identifying the treatments which are more likely to be successful in each patient.
More about this Study:
Added Value: CIBERESUCICOVID is a study that brings together the main Spanish scientific societies related to respiratory diseases with critical COVID-19 patients.
